2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC). (September 2015) - Rivera, F.; Karthaus, M.; Hecht, J.R.; Fasola, G.; Canon, J.L.; Guan, X.; Demonty, G.; Schwartzberg, L.S.